Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer

[1]  N. Zgheib,et al.  The pharmacogenetics of drug metabolizing enzymes in the Lebanese population , 2014, Drug metabolism and drug interactions.

[2]  I. Cascorbi,et al.  Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients , 2011, European Journal of Clinical Pharmacology.

[3]  M. Balbaa,et al.  CYP1A1, CYP2E1, and GSTM1 gene polymorphisms and susceptibility to colorectal and gastric cancer among Lebanese. , 2011, Genetic testing and molecular biomarkers.

[4]  J. Andrade,et al.  Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer , 2011, Cancer Chemotherapy and Pharmacology.

[5]  G. Hortobagyi,et al.  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.

[6]  D Jamieson,et al.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide , 2010, British Journal of Cancer.

[7]  R. Gray,et al.  Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study , 2010, Breast Cancer Research.

[8]  M. Dolan,et al.  Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. , 2009, Pharmacogenomics.

[9]  Yusuke Nakamura,et al.  Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients , 2009, Journal of Human Genetics.

[10]  Hongbing Wang,et al.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. , 2008, Current drug metabolism.

[11]  Jos H Beijnen,et al.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide , 2008, Pharmacogenetics and genomics.

[12]  K. Al-Kuraya,et al.  Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population , 2008, Leukemia & lymphoma.

[13]  Ncbi.  National Center for Biotechnology Information , 2008 .

[14]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Mukai,et al.  Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients , 2007, Pharmacogenetics and genomics.

[16]  C. Ambrosone,et al.  The role of genetic variability in drug metabolism pathways in breast cancer prognosis. , 2006, Pharmacogenomics.

[17]  E. Kimby,et al.  Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  O. Colvin,et al.  Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Zeruesenay Desta,et al.  Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. , 2004, Arthritis and rheumatism.

[20]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[21]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[22]  Moustapha Hassan,et al.  Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes , 2003, European Journal of Clinical Pharmacology.

[23]  H. Jinno,et al.  Functional characterization of cytochrome P450 2B6 allelic variants. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D. Berry,et al.  Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[26]  D. Waxman,et al.  Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[27]  F. Appelbaum,et al.  Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients , 1998, Clinical pharmacology and therapeutics.

[28]  J. Slattery,et al.  Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. , 1997, Cancer research.

[29]  J. Goldstein,et al.  Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.